Takeda Pharmaceutical Company Limited [TAK] gain 4.40% so far this year. What now?


Takeda Pharmaceutical Company Limited [NYSE: TAK] traded at a low on 07/13/22, posting a -1.25 loss after which it closed the day’ session at $14.23. The company report on July 11, 2022 that Takeda Announces the Submission of its Corporate Governance Report to the Tokyo Stock Exchange.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502/NYSE:TAK) today announced that it has filed its Corporate Governance Report with the Tokyo Stock Exchange (“TSE”) in accordance with the regulations* for TSE listed companies. The Report can be accessed on Takeda’s website at: https://www.takeda.com/who-we-are/corporate-governance/.

This report is prepared based on the revised Corporate Governance Code as in effect as of June 11, 2021. It describes the latest corporate governance features of our Company, including the new structure of the Board of Directors after the 146th General Shareholder’s Meeting held on June 29, 2022.

The results of the trading session contributed to over 3418367 shares changing hands. Over the past one week, the price volatility of Takeda Pharmaceutical Company Limited stands at 0.96% while the volatility over the past one month is 1.25%.

The market cap for TAK stock reached $45.23 billion, with 3.11 billion shares outstanding and 3.06 billion shares in the current float. Compared to the average trading volume of 2.52M shares, TAK reached a trading volume of 3418367 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Takeda Pharmaceutical Company Limited [TAK]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TAK shares is $19.05 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TAK stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Morgan Stanley have made an estimate for Takeda Pharmaceutical Company Limited shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on October 07, 2021. The new note on the price target was released on April 19, 2021, representing the official price target for Takeda Pharmaceutical Company Limited stock. Previously, the target price had yet another raise to $19.50, while Cowen analysts kept a Market Perform rating on TAK stock.

The Average True Range (ATR) for Takeda Pharmaceutical Company Limited is set at 0.19, with the Price to Sales ratio for TAK stock in the period of the last 12 months amounting to 1.72. The Price to Book ratio for the last quarter was 1.06, with the Price to Cash per share for the same quarter was set at 2.02. Price to Free Cash Flow for TAK in the course of the last twelve months was 8.59 with Quick ratio for the last quarter at 0.80.

How has TAK stock performed recently?

Takeda Pharmaceutical Company Limited [TAK] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.35. With this latest performance, TAK shares gained by 6.27% in over the last four-week period, additionally sinking by -0.07% over the last 6 months – not to mention a drop of -15.10% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TAK stock in for the last two-week period is set at 54.96, with the RSI for the last a single of trading hit 56.44, and the three-weeks RSI is set at 52.71 for Takeda Pharmaceutical Company Limited [TAK]. The present Moving Average for the last 50 days of trading for this stock 14.12, while it was recorded at 14.39 for the last single week of trading, and 14.37 for the last 200 days.

Takeda Pharmaceutical Company Limited [TAK]: Deeper insight into the fundamentals

Takeda Pharmaceutical Company Limited’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.80 and a Current Ratio set at 1.20.

Earnings analysis for Takeda Pharmaceutical Company Limited [TAK]

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TAK. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Takeda Pharmaceutical Company Limited go to 0.58%.

Insider trade positions for Takeda Pharmaceutical Company Limited [TAK]

There are presently around $874 million, or 1.90% of TAK stock, in the hands of institutional investors. The top three institutional holders of TAK stocks are: BSN CAPITAL PARTNERS LTD with ownership of 4,680,000, which is approximately New of the company’s market cap and around 0.01% of the total institutional ownership; MONDRIAN INVESTMENT PARTNERS LTD, holding 4,319,715 shares of the stock with an approximate value of $62.25 million in TAK stocks shares; and PARAMETRIC PORTFOLIO ASSOCIATES LLC, currently with $61.33 million in TAK stock with ownership of nearly 25.363% of the company’s market capitalization.

Positions in Takeda Pharmaceutical Company Limited stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 140 institutional holders increased their position in Takeda Pharmaceutical Company Limited [NYSE:TAK] by around 12,951,347 shares. Additionally, 120 investors decreased positions by around 17,702,846 shares, while 68 investors held positions by with 29,969,328 shares. The mentioned changes placed institutional holdings at 60,623,521 shares, according to the latest SEC report filing. TAK stock had 43 new institutional investments in for a total of 5,829,194 shares, while 49 institutional investors sold positions of 6,920,354 shares during the same period.